SecurityIZEA / IZEA Inc. (46603N301)
Institutional Owners19 (1 N-Q Owners)
Institutional Shares1,342,422 - 22.97% (ex. N-Q)
Common Shares Outstanding5,844,744 shares (as of 2018-03-31)
Institutional Value$ 4,911,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

IZEA / IZEA Inc. Institutional Ownership

IZEA Inc. (NASDAQ:IZEA) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,342,422 shares. Largest shareholders include AWM Investment Company, Inc., Vanguard Group Inc, Royce & Associates LLC, Perkins Capital Management Inc, Essex Investment Management Co Llc, Bank of New York Mellon Corp, Geode Capital Management, Llc, Acadian Asset Management Llc, Macquarie Group Ltd, and A.R.T. Advisors, LLC.
IZEA Inc. (NASDAQ:IZEA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/izea"><img src="https://images.fintel.io/us-izea-so.png" alt="IZEA / IZEA Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,901 24,901 0.00 112 91 -18.75
2018-05-15 13F-HR Bank of New York Mellon Corp 29,505 27,944 -5.29 133 102 -23.31
2018-05-15 13F-HR DEUTSCHE BANK AG\ 2,700 1,300 -51.85 12 4 -66.67
2018-05-14 13F-HR Virtu Financial LLC 13,497 0 -100.00 61 0 -100.00
2018-04-26 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 93,066 84,510 -9.19 421 309 -26.60
2018-05-15 13F-HR UBS Group AG 0 374 0 1
2018-05-15 13F-HR VANGUARD GROUP INC 317,124 305,678 -3.61 1,433 1,119 -21.91
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 18,516 0 -100.00 81 0 -100.00
2018-05-09 13F-HR IFP Advisors, Inc 1,000 1,000 0.00 5 4 -20.00
2018-05-09 13F-HR BlackRock Inc. 3,697 3,865 4.54 17 14 -17.65
2018-02-28 N-Q Ishares Trust (see advisory)
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 8,000 0 -100.00 36 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 68 68 0.00 0 0
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 18,690 21,791 16.59 84 79 -5.95
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 6 6 0.00 0 0
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 11,035 40
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 100 0 -100.00 1 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 0 10,300 0 38
2018-05-11 13F-HR MACQUARIE GROUP LTD 4,056 21,256 424.06 18 78 333.33
2018-02-15 13F-HR JANE STREET GROUP, LLC 12,922 0 -100.00 92 0 -100.00
2018-02-09 13F-HR Timber Hill LLC 10,909 0 -100.00 77 0 -100.00
2018-05-15 13F-HR A.R.T. Advisors, LLC 16,407 60
2018-05-14 13F-HR Royce & Associates LLC 161,176 161,176 0.00 729 590 -19.07
2018-05-10 13F-HR AWM Investment Company, Inc. 543,216 543,216 0.00 2,455 1,988 -19.02
2018-04-23 13F-HR PERKINS CAPITAL MANAGEMENT INC 107,595 107,595 0.00 486 394 -18.93

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( IZEA / IZEA Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

IZEA's (IZEA) CEO Ted Murphy on Q4 2017 Results - Earnings Call Transcript

2018-04-20 seekingalpha
Greetings and welcome to the IZEA’s Incorporated Q4 and Annual 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (1-1)

BRIEF-Izea Announces Date Change For FY 2017 Earnings Results Conference Call

2018-03-28 reuters
* IZEA INC - CONF CALL TO REVIEW AND DISCUSS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS WILL NOW BEGIN AT 5:00 P.M. EASTERN STANDARD TIME ON APRIL 2, 2018 Source text for Eikon: Further company coverage: (1-0)

CUSIP: 46603N301